Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04121793 · ClinicalTrials.gov registry record
Objective Quality of Life Detection Validation
A clinical trial, sponsored by Great Lakes NeuroTechnologies.
- Completed
- Registry status
- 10
- Enrollment target
NCT04121793: Completed study, sponsored by Great Lakes NeuroTechnologies.
NCT04121793 is a clinical trial that has completed, run by Great Lakes NeuroTechnologies. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04121793 has completed, sponsored by Great Lakes NeuroTechnologies.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
The purpose of this research study is to: * Collect data to use in the development of a standardized tool for identifying patients with Parkinson's disease (PD) who would benefit from advanced therapies (AT) such as deep brain stimulation (DBS) and drug pumps. * Determine the level to which specific activities reflect with quality of life in individuals with PD. * Obtain feedback from individuals with Parkinson's disease and clinicians on the usability of the system.
Primary Outcome
Kinesia 360 scoring of Parkinson's Disease motor symptoms (tremor, slowness, dyskinesia, gait): The Kinesia 360 system translates recorded motion into 0-4 scores that correlate to rating scales used by clinicians (lower scores are signifiers of better outcomes and higher scores signify worse outcomes). A separate 0-4 score is generated for tremor, slowness, and dyskinesia, and gait is tracked for step count and percent of day walking.
Interventions
- DEVICE Kinesia 360 and Smartphone sensors
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-09-20 |
| Est. Completion | 2020-06-30 |
What the finished NCT04121793 record still lists
NCT04121793 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Kinesia 360 and Smartphone sensors is the first listed.
NCT04121793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04121793 about?
NCT04121793 is a clinical study titled "Objective Quality of Life Detection Validation". The purpose of this research study is to: * Collect data to use in the development of a standardized tool for identifying patients with Parkinson's disease (PD) who would benefit from advanced therapies (AT) such as deep brain stimulation (DBS) and drug pumps. * Determine the level to which specifi...
What is the current status of trial NCT04121793?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2019-09-20. Estimated completion is 2020-06-30.
What interventions are being tested in trial NCT04121793?
The interventions under investigation include: Kinesia 360 and Smartphone sensors (DEVICE).
Who is sponsoring clinical trial NCT04121793?
This trial is sponsored by Great Lakes NeuroTechnologies, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI